AIDS

California Opens Nation’s First Transgender Facility Vote Center

Retrieved on: 
Wednesday, February 28, 2024
LGBTQ+, White House, Federal Government, Public Policy, Government, State, Local, Consumer, Elections, Campaigns, Unique, AIDS Healthcare Foundation, AIDS, AHF, HRC, Gender, Transgender, Trans, Connie Norman, NEX, TGI, UWC, Disease, Film industry

The Connie Norman Transgender Empowerment Center (CONOTEC), a facility providing comprehensive resources, training, support, and medical services for Transgender people living in Los Angeles, will serve as an officially designated Los Angeles County Vote Center for the upcoming March 5th California primary as well as for the November 2024 general/presidential election.

Key Points: 
  • The Connie Norman Transgender Empowerment Center (CONOTEC), a facility providing comprehensive resources, training, support, and medical services for Transgender people living in Los Angeles, will serve as an officially designated Los Angeles County Vote Center for the upcoming March 5th California primary as well as for the November 2024 general/presidential election.
  • CONOTEC is the first Transgender facility nationwide to serve as an official election Vote Center.
  • The Connie Norman Transgender Empowerment Center, 1001 N. Martel St., Los Angeles, CA 90046
    Los Angeles County Vote Centers either commit to 10-day or 4-day voting periods, both offering early voting periods that end on March 5th.
  • The Connie Norman Center is a 4-day Vote Center.

Hillsinai Learning, in Partnership With Vedhik AI Schools, Selects iLearningEngines as Its AI Learning Automation Platform

Retrieved on: 
Wednesday, February 28, 2024
Technology, Software, AIDS, Continuing, Training, Health, Primary, Secondary, Education, Artificial Intelligence, Knowledge, Entrepreneurship, School, AI, Partnership, Culture, Gulf Cooperation Council, GCC, Curriculum, Learning, Student, Tutoring

iLearningEngines, Inc. (“iLearningEngines” or “the Company”), a leader in AI-powered learning automation and information intelligence for corporate and educational use, today announced that Hillsinai Learning, in partnership with Vedhik AI Schools, has selected iLearningEngines as its AI learning automation platform.

Key Points: 
  • iLearningEngines, Inc. (“iLearningEngines” or “the Company”), a leader in AI-powered learning automation and information intelligence for corporate and educational use, today announced that Hillsinai Learning, in partnership with Vedhik AI Schools, has selected iLearningEngines as its AI learning automation platform.
  • Through this new partnership, more than 500,000 students will get access to high quality education and competency resources.
  • “This is an incredible milestone for iLearningEngines and a true testament to the power of our platform,” said Harish Chidambaran, CEO of iLearningEngines.
  • Our work with iLearningEngines and Hillsinai Learning will serve as a blueprint for other educational institutions to integrate innovative technology into their curriculum and classrooms more effectively.”
    For more information about iLearningEngines or its partnership with Hillsinai Learning and Vedhik AI Schools, please visit: www.iLearningEngines.com .

Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

Retrieved on: 
Tuesday, February 27, 2024
Pharmaceutical, General Health, Professional Services, Women, Philanthropy, Hospitals, Teens, LGBTQ+, Fund Raising, Biotechnology, Science, DEI (Diversity, Equity and Inclusion), AIDS, Consumer, Research, Health, Woman, National Association, Gilead Sciences, Investment, Transgender, General counsel, Corporate Affairs, Organization, Health equity, Community, Ageing, HIV, Pharmaceutical industry

(Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic.

Key Points: 
  • (Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic.
  • In 2021, Black women accounted for 53% of new HIV diagnoses among women aged 16 and older in the United States, despite comprising only 14% of the women living in the country.
  • Additionally, Black Transgender women have the highest rates of new HIV diagnoses among Transgender people and are more likely to go undiagnosed and untreated in comparison to their peers.
  • These inequities are exacerbated by significant gaps in the delivery of effective and culturally relevant HIV prevention information and care services for Black women and girls.

U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

Retrieved on: 
Monday, February 26, 2024
AIDS, FDA, Health, Hospitals, Pharmaceutical, Biotechnology, Infection, Division, Week, Doctor of Philosophy, Gilead Sciences, HIV-1, Drug resistance, MD, PWH, Science, Food, DHHS, Boxed warning, Hospital, Life, Risk, Safety, NRTI, RNA, History, Public, Guideline, DTG, Harvard Medical School, Mutation, Tablet, HIV, Vaccine

HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.

Key Points: 
  • HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.
  • The M184V/I resistance mutation has been found to be present in a range (22-63%) of PWH with pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs) across various HIV subtypes.
  • “Clinical data have established Biktarvy as a long-term HIV treatment option for a broad range of PWH.
  • There were also zero cases of treatment-emergent resistance to Biktarvy, regardless of known or suspected pre-existing M184V/I resistance, in the final resistance analysis population.

AHF Backs Congressional Push to Protect HIV/AIDS Funding

Retrieved on: 
Monday, February 26, 2024
White House, Federal Government, Public Policy, Healthcare Reform, Pharmaceutical, Social Activism, Communications, General Health, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Congressional News, Views, Government, Foundation, AIDS, Health, President Trump, Congress, AHF, AIDS Healthcare Foundation, House, HIV, HIV/AIDS denialism, Pharmaceutical industry

It would be penny wise and pound foolish to undo the amazing progress that has been made in combatting HIV in America,” said Michael Weinstein, AHF president and cofounder.

Key Points: 
  • It would be penny wise and pound foolish to undo the amazing progress that has been made in combatting HIV in America,” said Michael Weinstein, AHF president and cofounder.
  • “Republicans should remember that it was former President Trump who inaugurated the Ending the HIV Epidemic in the U.S. program.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240223537702/en/

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
Monday, February 26, 2024
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, Senior, Hepatitis B, CROI, Hook effect, RWE, STR, Viral, Virus, DTG, Mortality, Lenacapavir, Hepatitis, HBV, Vesatolimod, Fungal infection, HIV-1, MDR, PWH, HDV, Boxed warning, European, Islatravir, Tablet, European Commission, Liver disease, Omicron, Conference, Safety, ART, Civil service commission, Abstract, Bictegravir, Natural history, Virology, Emtricitabine, Gilead Sciences, MD, Food, Coinfection, Immunodeficiency, European Economic Area, Risk, Prevalence, Dexamethasone, Patient, Tuberculosis, INSIGHT, HIV, Pharmaceutical industry

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

AHF Backs Africa CDC Push to Curb Cholera

Retrieved on: 
Thursday, February 22, 2024
Infectious Diseases, Advocacy Group Opinion, Public Policy, Government, AIDS, Health, Pharmaceutical, General Health, Other Policy Issues, AHF, Cholera, African Union, Global health, Drinking water, AIDS Healthcare Foundation, African Medicines Agency, Death, Pharmaceutical industry

“Just from the beginning of this year, nearly 900 people have died from cholera across Africa.

Key Points: 
  • “Just from the beginning of this year, nearly 900 people have died from cholera across Africa.
  • This is yet another tragic example of inequity in global health that the African Union, Africa CDC, and leaders on the continent must prioritize and address as quickly as possible,” said AHF Africa Bureau Chief, Dr. Penninah Iutung.
  • “Regional self-sufficiency through the production of essential vaccines and medical commodities in Africa should be the end goal—COVID-19 made that clear.
  • As a model for addressing such issues, AHF supported the drilling of a potable water well in Benue State, Nigeria, in 2020.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, AIDS, Health, COVID-19, Infectious Diseases, Health Technology, Clinical Trials, Infection, Bangladesh Technical Education Board, RSV, CHB, Influenza, Peginterferon-alfa, HIV Vaccine Trials Network, GSK, Research, Investment, AASLD, HDV, MBA, Cirrhosis, HHS, Administration, Conditional sentence, Hepatology, RNA, Respiratory syncytial virus, ASPR, COVID, Patient, Family, HCMV, Bill, Development, HIV, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

Legacy of Aladar Marberger: Pioneering Gallerist and AIDS Activist’s Art Collection Goes to Auction

Retrieved on: 
Wednesday, February 21, 2024
Arts, Museums, LGBTQ+, Entertainment, Consumer, Women, Men, Collection, Ballet company, Multimedia, Courage, Fischbach Gallery, Telephone, Fine art, AIDS, Friends, EST, Exhibition, Sale, Joffrey Ballet, Personality, TIME, Carnegie Mellon University, Life, Vanity Fair, Human, History, Pfahler, Painting, Disease, Portrait, Diagnosis, Nightclub

Rago/Wright proudly announces the auction “Living Out Loud: The A. Aladar Marberger Collection,” slated to go on sale on March 13, 2024.

Key Points: 
  • Rago/Wright proudly announces the auction “Living Out Loud: The A. Aladar Marberger Collection,” slated to go on sale on March 13, 2024.
  • The collection celebrates the remarkable life and enduring legacy of Aladar Marberger, a central figure in New York's 1970s and 1980s art scene.
  • Painted soon after Marberger’s AIDS diagnosis, a leading work of the collection is Elaine de Kooning’s “Aladar #3” (est.
  • “Aladar Marberger was someone who approached both art and life with excitement, generosity, and courage,” says Meredith Hilferty, Rago Director of Fine Art.

AHF Honors and Remembers Indomitable AIDS Activist Hydeia Broadbent

Retrieved on: 
Wednesday, February 21, 2024
AIDS, Public Policy, Government, Health, Infectious Diseases, Other Policy Issues, General Health, Public, Methodism, The Oprah Winfrey Show, Multimedia, AIDS Healthcare Foundation, AHF, Sleep, Life, Death, Selma University, HIV

AIDS Healthcare Foundation (AHF) mourns the death of lifelong AIDS activist Hydeia Broadbent who passed away in her sleep yesterday at the age of 39.

Key Points: 
  • AIDS Healthcare Foundation (AHF) mourns the death of lifelong AIDS activist Hydeia Broadbent who passed away in her sleep yesterday at the age of 39.
  • View the full release here: https://www.businesswire.com/news/home/20240221195521/en/
    Lifelong AIDS activist Hydeia Broadbent, far right, rode on AHF’s award-winning 2013 Tournament of Roses parade float titled “The Global Face of AIDS,” on which she represented North American individuals living with AIDS.
  • Over the years, Broadbent partnered with AHF on several AIDS advocacy and awareness campaigns, including riding on AHF’s award-winning 2013 Tournament of Roses parade float titled “The Global Face of AIDS” on which she represented North American individuals living with AIDS.
  • AHF’s “AIDS is a Civil Rights Issue” campaign, Selma 2015: During the 50th Anniversary of the Selma to Montgomery March, Hydeia Broadbent joined Rev.